An open-access detailed editorial from the official periodical of the International Association for the Study of Lung Cancer
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Genetics
November 21, 2020
A scholarly and sober narrative review on , as the authors state, a ' hot topic' that is already being debated in Multidisciplinary Meetings and Lung Cnacer Boards.
February 3, 2020
This interesting study compared bronchial epithelial mutation burden, the primary source of new lung cancers, among nonsmokers, former smokers, and current smokers. Smoking typically adds 1,000 to 10,000 mutations per cell. Smoking cessation in this study was associated with replenishment of the abnormal epithelium with cells that are typical of no
November 7, 2019
This brief overview of recently presented improvements in lung cancer therapy highlights the substantial benefits of newer chemotherapy and immunotherapy regimens that are transforming the outlooks of many patients with advanced lung cancer.
August 20, 2019
Interesting follow-up study of 208 pulmonary ground -glass opacities in 160 subjects, with a yield of three adenocardinomas.
December 3, 2018
Park and colleagues genotyped cancer tissue for epidermal growth factor receptor (EGFR) mutations in patients with complete resection for lung adenocarcinoma who had a recurrence. Lung adenocarcinoma with EGFR gene mutations was associated with a longer disease-free interval than was the wild-type EGFR gene.
May 31, 2018
This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival. Tumor mutational burden was a marker for patient selection for immunotherapy.
May 23, 2018
This is among the first and largest summaries of the use of neoadjuvant PD-1 inhibitor (nivolumab) in patients with resectable lung cancer. The safety profile was adequate, 20 of 21 patients underwent complete resection, and the pathologic major response rate was 45%. The response was similar regardless of PD-L1 status, and response was related to
January 13, 2018
The authors studied survival in patients with multiple lung cancers and their associated genetic mutations. There was 90% discordance in driver mutations beween cancers in individual patients that was associated with favorable survival. The two patients in whom condordance was present suffered recurrent cancer.
October 24, 2017
A useful reminder of the substantial progress that has been made and the continuing challenges that we face in fighting this terrible disease.